A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: Does it justify ce threshold?

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Nimdet, Khachapon ^a   Chaiyakunapruk, Nathorn ^b,c,d,e   Vichansavakul, Kittaya ^a   Ngorsuraches, Surachat ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

^c NARESUAN UNIVERSITY   (Thailand)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINGENT VALUATION; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; FUNDING; GROSS NATIONAL PRODUCT; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; INTERNET; INTERVIEW; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TELEPHONE; WILLINGNESS TO PAY; WORLD HEALTH ORGANIZATION; ADULT; AGED; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMIC MODEL; FEMALE; HEALTH CARE COST; MALE; MIDDLE AGED; PSYCHOLOGY;

ADULT; AGED; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84928817222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122760     Document Type: Review

References (60)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in Health and Medicine. New York: Oxford University Press.
2. Grosse SD (2008) Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 8: 165-178. doi: 10.1586/14737167.8.2.165 PMID: 20528406
3. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH (2000) Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 19: 92-109. PMID: 10718025
4. McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26: 733-744. PMID: 18767894
5. Appleby J, Devlin N, Parkin D (2007) NICE's cost effectiveness threshold. BMJ 335: 358-359. PMID: 17717337
6. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19: 422-437. doi: 10.1002/hec.1481 PMID: 19382128
7. Institute for Health and Clinical Excellence (2013) Guide to the methods of technology appraisal 2013. Available: http://www.nice.org.uk/article/PMG9/chapter/Foreword. Accessed 2014 August 12.
8. George B, Harris A, Mitchell A (2001) Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics 19: 1103-1109. PMID: 11735677
9. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 20: 332-342. PMID: 10929856
10. World Health Organization. Choosing interventions that are cost effective. Available: http://www.who.int/choice/costs/CER-levels/en/. Accessed 2014 Dec 8.
11. World Health Organization. Macroeconomics and Health: investing in health for economic development. Geneva, Switzerland: World Health Organization: Report of the WHO Commission on Macroeconomics and Health 2001
12. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17: 1459-1471. PMID: 16847588
13. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7: 518-528. PMID: 15367247
14. Shillcutt SD, Walker DG, Goodman CA, Mills AJ (2009) Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 27: 903-917. doi: 10.2165/10899580-000000000-00000 PMID: 19888791
15. Johannesson M, Meltzer D (1998) Some reflections on cost-effectiveness analysis. Health Econ 7: 1-7. PMID: 9541079
16. Dolan P, Edlin R (2002) Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis? J Health Econ 21: 827-843. PMID: 12349884
17. Gyrd-Hansen D, Kjaer T (2012) Disentangling WTP per QALY data: different analytical approaches, different answers. Health Econ 21: 222-237. doi: 10.1002/hec.1709 PMID: 21254305
18. Mason H, Baker R, Donaldson C (2008) Willingness to pay for a QALY: past, present and future. Expert Rev Pharmacoecon Outcomes Res 8: 575-582. doi: 10.1586/14737167.8.6.575 PMID: 20528368
19. Bobinac A, Van Exel NJ, Rutten FF, Brouwer WB (2010) Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health 13: 1046-1055. doi: 10.1111/j.1524-4733.2010.00781.x PMID: 20825620
20. Bobinac A, Van Exel NJA, Rutten FFH, Brouwer WBF (2013) Valuing qaly gains by applying a societal perspective. Health Economics (United Kingdom) 22: 1272-1281.
21. Byrne MM, O'Malley K, Suarez-Almazor ME (2005) Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making 25: 655-666. PMID: 16282216
22. Gyrd-Hansen D (2003) Willingness to pay for a QALY. Health Econ 12: 1049-1060. PMID: 14673813
23. Pinto-Prades JL, Loomes G, Brey R (2009) Trying to estimate a monetary value for the ALY. J Health Econ 28: 553-562. doi: 10.1016/j.jhealeco.2009.02.003 PMID: 19327857
24. Robinson A, Gyrd-Hansen D, Bacon P, Baker R, Pennington M, Donaldson C, et al. (2013) Estimating a WTP-based value of a QALY: the 'chained' approach. Soc Sci Med 92: 92-104. doi: 10.1016/j.socscimed.2013.05.013 PMID: 23849283
25. Shiroiwa T, Igarashi A, Fukuda T, Ikeda S (2013) WTP for a QALY and health states: More money for severer health states? Cost Eff Resour Alloc 11: 22. doi: 10.1186/1478-7547-11-22 PMID: 24128004
26. Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P (2013) Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res 5: 29-36. doi: 10.2147/CEOR.S38062 PMID: 23345984
27. Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC (2010) Willingness to pay per quality adjusted life-year: Is one threshold applicable for all decision-making? Value in Health 13: A538.
28. King JT Jr, Tsevat J, Lave JR, Roberts MS (2005) Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation. Medical Decision Making 25: 667-677. PMID: 16282217
29. Zethraeus N (1998) Willingness to pay for hormone replacement therapy. Health Econ 7: 31-38. PMID: 9541082
30. Oosterhoff J (1994) Trimmed mean or sample median? Statistics & Probability Letters 20: 401-409.
31. The World Bank. Official exchange rate (LCU per US$, period average). Available: http://data.worldbank.org/indicator/PA.NUS.FCRF. Accessed 2014 Jul 20.
32. The World Bank. GDP per capita (current US$). Available: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 2014 Jul 20.
33. Martin-Fernandez J, Polentinos-Castro E, del Cura-Gonzalez MI, Ariza-Cardiel G, Abraira V, Gil-Perez S, et al. (2014) Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences. BMC Health Serv Res 14: 287. doi: 10.1186/1472-6963-14-287 PMID: 24989615
34. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Rusinak D, et al. (2009) Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmacoeconomics 27: 1005-1016. doi: 10.2165/11314000-000000000-00000 PMID: 19908925
35. Johnson FR (2005) Einstein on willingness to pay per QALY: is there a better way? Med Decis Making 25: 607-608. PMID: 16282210
36. Weinstein MC (2008) How much are Americans willing to pay for a quality-adjusted life year? Med Care 46: 343-345. doi: 10.1097/MLR.0b013e31816a7144 PMID: 18362811
37. Olsen JA, Smith RD (2001) Theory versus practice: a review of 'willingness-to-pay' in health and health care. Health Econ 10: 39-52. PMID: 11180568
38. Hammit JK (2002) QALYs versus WTP. Risk Anal 22: 985-1001. PMID: 12442993
39. Baker R, Chilton S, Donaldson C, Jones-Lee M, Lancsar E, Manson H, et al. (2011) Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Econ Policy Law 6: 435-447. doi: 10.1017/S1744133111000181 PMID: 21854688
40. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B (1998) Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 51: 667-676. PMID: 9743315
41. Franic DM, Pathak DS, Gafni A (2005) Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey. J Clin Epidemiol 58: 291-303. PMID: 15718119
42. Franic DM, Bothe AK, Bramlett RE (2012) A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years. J Fluency Disord 37: 300-313. doi: 10.1016/j.jfludis.2012.04.005 PMID: 23218213
43. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M (1999) Quality of life, healthstate utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 141: 1067-1075. PMID: 10606854
44. Pinto-Prades JL, Sanchez-Martinez FI, Corbacho B, Baker R (2014) Valuing QALYs at the end of life. Soc Sci Med 113: 5-14. doi: 10.1016/j.socscimed.2014.04.039 PMID: 24820408
45. Richardson J, Iezzi A, Sinha K, Khan MA, McKie J (2014) An instrument for measuring the social willingness to pay for health state improvement. Health Econ 23: 792-805. doi: 10.1002/hec.2950 PMID: 23824989
46. Blumenschein K, Johannesson M (1998) Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 80: 189-194. PMID: 9494453
47. Haninger K, Hammitt JK (2011) Diminishing willingness to pay per quality-adjusted life year: valuing acute foodborne illness. Risk Anal 31: 1363-1380. doi: 10.1111/j.1539-6924.2011.01617.x PMID: 21488924
48. Tolbert DV, McCollister KE, LeBlanc WG, Lee DJ, Fleming LE, Muennig P (2014) The economic burden of disease by industry: Differences in quality-adjusted life years and associated costs. Am J Ind Med 57: 757-763. doi: 10.1002/ajim.22322 PMID: 24954889
49. Gafni A (2006) Economic Evaluation of Health-care Programmes: Is CEA Better than CBA? Environmental & Resource Economics 34: 407-418.
50. Boersma C, Broere A, Postma MJ (2010) Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis. Value Health 13: 853-856. doi: 10.1111/j.1524-4733.2010.00736.x PMID: 21054659
51. Nuijten MJ, Dubois DJ (2011) Cost-utility analysis: current methodological issues and future perspectives. Front Pharmacol 2: 29. doi: 10.3389/fphar.2011.00029 PMID: 21713127
52. Bateman IJ, Carson RT, Day B, Hanemann M, Hanley N, Hett T, et al. 2002. Economic valuation with stated preference techniques. Edward Elgar: Cheltenham.
53. Lancsar E, Louviere J (2008) Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 26: 661-677. PMID: 18620460
54. Mangham LJ, Hanson K, McPake B (2009) How to do (or not to do) . . . Designing a discrete choice experiment for application in a low-income country. Health Policy Plan 24: 151-158. doi: 10.1093/heapol/czn047 PMID: 19112071
55. Louviere JJ, Flynn TN, Carson RT (2010) Discrete Choice Experiments Are Not Conjoint Analysis. Journal of Choice Modelling 3: 57-72.
56. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: www.cochrane-handbook.org. Accessed 2015 Jan 15
57. Donaldson C (1999) Valuing the benefits of publicly-provided health care: does 'ability to pay' preclude the use of 'willingness to pay'? Soc Sci Med 49: 551-563. PMID: 10414814
58. Bridges JF (2003) Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy 2: 213-224. PMID: 15119540
59. Gryd-Hasen (2007) Looking for willingness to pay (WTP) threshold for a QALY - does it make sense? A critical view. ISPOR Connection 13: 5-8.
60. Hutton J (1992) Cost-benefit analysis in health care expenditure decision-making. Health Econ 1: 213-216. PMID: 1341937